当前货币:CNY

您的购物车中没有商品。

Acceptable Risk in Biomedical Research: European Perspectives

Acceptable Risk in Biomedical Research: European Perspectives

  • 作者:
  • 出版商: Springer-Verlag
  • ISBN: 9789400795532
  • 规格: Paperback
  • 适应领域: Netherlands ? 免责申明:
    Countri(es) stated herein are used as reference only
¥1,124.24
发货时间:大约 4-5 weeks
Extra 2-10 working days if shipping address outside Hong Kong
Free delivery Hong Kong?
Hong Kong: free delivery (order over HKD 1000)
  • 描述 
  • 大纲 
  • 详细

    This book is the first major work that addresses a core question in biomedical research: the question of acceptable risk. The acceptable level of risks is regulated by the requirement of proportionality in biomedical research law, which state that the risk and burden to the participant must be in proportion to potential benefits to the participant, society or science. This investigation addresses research on healthy volunteers, children, vulnerable subjects, and includes placebo controlled clinical trials. It represents a major contribution towards clarifying the most central, but also the most controversial and complex issue in biomedical research law and bioethics. The EU Clinical Trial Directive, the Council of Europe's Oviedo Convention (and its Additional Protocol), and national regulation in member states are covered. It is a relevant work for lawyers and ethicists, and the practical approach makes a valuable tool for researchers and members of research ethics committees supervising biomedical research.

  • 1. Introduction
    2. Method and material
    3. Initial conceptual clarifications
    4. Origins of the requirement of proportionality
    5. The purpose of the requirement of proportionality
    6. Introduction: Part II
    7. Which risks, burdens and potential benefits are relevant?
    8. How to estimate risks, burdens, and potential benefits
    9. The requirement of proportionality - initial clarifications
    10. Therapeutic research
    11. Nontherapeutic research
    12. Nontherapeutic research on "vulnerable" participants
    13. Non-interference with necessary clinical interventions and the no harm rule
    14. Especially on randomised clinical trials, including placebo controlled clinical trials
    15. Acceptable Risks and Burdens to Others than the Participant
    16. Later developments during the course of the research
    17. Legal effects of the requirement of proportionality
    18. Summary of results
    19. Recommendations
    20. Perspectives
    21. Appendix

你可能需要